已传文件：photo/1768267912.png
Selected Article
Hepatocellular carcinoma (HCC) exhibits profound glycolytic reprogramming, driving tumor growth, impairing apoptosis, and suppressing immune responses, leading to resistance to conventional therapies. To overcome this challenge, we developed a stimulus-responsive nanozyme composed of glucose oxidase (GOx) encapsulated in a pH-sensitive lipid-gelatin-peptone (LGP) nanogel. This tumor-selective nanozyme consumes glucose within tumors under acidic conditions, inducing oxidative and endoplasmic reticulum stress,Upregulates death receptors and sensitizes hepatocytes to TRAIL- and doxorubicin (DOX)-induced apoptosis. The co-delivery of GOx and DOX in nanoenzymes reprograms tumor immune metabolism, enhances immunogenic cell death, and promotes the release of damage-associated molecular patterns (DAMPs). These changes stimulate dendritic cell maturation and cytotoxic CD8 T cell activation. Transcriptome analysis confirmed that this nanoenzyme remodels the immunosuppressive microenvironment by inhibiting metabolic pathways and activating immune-related gene programs.When combined with anti-PD-1 checkpoint blockade, this nanozyme can induce potent tumor regression in an orthotopic HCC model, eliminate metastasis, and cause no systemic toxicity. Overall, this work introduces a multifunctional tumor-responsive nanozyme that integrates metabolic intervention, apoptosis initiation, and immune activation to overcome therapeutic resistance in HCC.
Original link
Stimuli-Responsive Nanozyme Reprograms Tumor Immunometabolism and Overcomes Therapeutic Resistance in Hepatocellular Carcinoma
ACS Nano ( IF 16 )
Pub Date : 2026-01-06
DOI: 10.1021/acsnano.5c11352
Yen-Nhi Ngoc Ta,Van-Anh Thi Nguyen,Thu-Thuy Can,Meng-Cheng Hsieh,Bang Giang Thi Cao,Dehui Wan,Chian-Hui Lai,Chun-Chieh Wu,Fu-Fei Hsu,Yu-Ting Yen,Shen-Nien Wang,Yunching Chen
